CISPLATIN-INDUCED VOMITING DEPENDS ON CIRCADIAN TIMING

REFERENCES

• Weiner M. W., Jacobs C. Mechanism of Cisplatin Nephrotoxicity. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1987; 42: 2974–2978
   Google Scholar
• Hadley D., Herr H. W. Peripheral Neurotoxicity Associated with Cis-dichlorodiammineplatinum (II) Treatment. Cancer 1979; 44: 2026–2028
   PubMedGoogle Scholar
• Wiltshaw E. A Review of Clinical Experience with Cis-platin Diammine Chloride. Biochimie 1987; 60: 1972–1978
   Google Scholar
• Lazlo J. Nausea and Vomiting as Major Complications of Cancer Chemotherapy. Drugs 1983; 25(suppl. 1)1–7
   Google Scholar
• Von Hoff D. D., Schilsky R., Reichart C., Reddick R. L., Rozencweig M., Young R. C., Muggia F. M. Toxic Effects of Cis-dichlorodiammineplatinium(II) in Man. Cancer Treat. Rep. 1979; 63: 1527–1531
   PubMedGoogle Scholar
• Hrushesky W. J.M., Lévi F. A., Halberg F., Kennedy B. Circadian Stage Dependence of Cis-diamminedichloroplatinum Lethal Toxicity in Rats. Cancer Res. 1982; 42: 945–940
   PubMed Web of Science ®Google Scholar
• Lévi F. A., Hrushesky W. J.M., Blonquist C. H., Lakuta D. J., Haus E., Halberg F., Kennedy B. Reduction of Cis-diamminedichloroplatinum Nephrotoxicity in Rats by Optimal Circadian Drug Timing. Cancer Res. 1982; 42: 950–955
   PubMed Web of Science ®Google Scholar
• Hrushesky W. J.M. Circadian Timing of Cancer Chemotherapy. Science 1985; 228: 73–75
   PubMed Web of Science ®Google Scholar
• Ortega L. D., Cever R. C., Funes H. C., Gallego E. D. Sleep Protects Against Chemotherapy Induced Emesis. Cancer 1996; 77: 1566–1570
   PubMedGoogle Scholar
• Roemeling R. V., Christiansen N. P., Hrushesky W. J.M. Lack of Anti-emetic Effect of High-dose Metoclopramide. J. Clin. Oncol. 1985; 3: 1273–1276
   PubMed Web of Science ®Google Scholar
• Miner R. W.D., Sanger G. J. .Inhibition of Cisplatin-Induced Vomiting by Selective 5 Hydroxytryptamine M-Receptor Antagonism. Br. J. Pharmacol. 1986; 88: 497–499
   PubMed Web of Science ®Google Scholar
• Costall B., Domeney A. S.M., Naylor R. J., Tattersall F. D. 5-Hydroxytryptamine M-Receptor Antagonism to Prevent Cisplatin-Induced Emesis. Neuropharmacology 1986; 25: 959–961
   PubMed Web of Science ®Google Scholar
• Stables R., Andrews P. L., Costall B., Gunning S. J., Hawthorn J., Naylor R. J., Tyers M. B. Anti-emetic Properties of the 5HT3 Antagonist, GR38032F. Cancer Treat. Rev. 1987; 14: 333–336
   PubMed Web of Science ®Google Scholar
• Marty M., Pouillart P., Scholl S., Droz J. P., Azab M., Brion N., Pujade-Lauraine E., Paule B., Paes D., Bons J. Comparison of the 5-Hydroxytryptamine- 3(Serotonin) Antagonist Ondansetron(GR38032) with High-dose Metoclopramide in the Control of Cisplatin-Induced Emesis. N. Engl. J. Med. 1990; 332: 816–821
   Google Scholar
• Noto A., Ogawa Y., Mori S., Yoshida M., Kitakaze T., Hori T., Nakamura M., Miyake T. Simple, Rapid Spectrophotometry of Urinary N-Acetyl-(D-gulucosaminidase, with Use of a new Chromogenic Substrate. Clin. Chem. 1983; 29: 1713–1716
   PubMed Web of Science ®Google Scholar
• Nerenz D. R., Leventhal H., Easterling D. V. Anxiety and Drug Taste as Predictors of Anticipatory Nausea in Cancer Chemotherapy. J. Clin. Oncol. 1986; 4: 224–233
   PubMed Web of Science ®Google Scholar
• Hrushesky W. J.M., Bjarnason G. A. Circadian Cancer Therapy. J. Clin. Oncol. 1993; 11: 1403–1417
   PubMedGoogle Scholar
• Ostraw S., Egorin M. J., Hahn D., Markus S., Chang P., LeRoy A., Bachur N. R., Wiernik P. H. High-dose Cisplatin Therapy Using Mannitol Versus Furosemide Diuresis: Comparative Pharmacokinetics and Toxicity. Cancer Treat. Rep. 1981; 65: 73–78
   Google Scholar
• Numico G., Benasso M., Vannozzi M. O., Merlano M., Rosso R., Viale M., Esposito M. Hydration Regimen and Hematological Toxicity of a Cisplatin-based Chemotherapy Regimen. Clinical Observations and Pharmacokinetic Analysis. Anticancer Res. 1998; 18: 1313–1318
   PubMedGoogle Scholar
• Pera M. F.J., Harder H. C. Effects of Mannitol and Furosemide Diuresis on Cisdiamminedichloroplatinum (II) Antitumor Activity and Toxicity to Host-Renewing Cell Populations in Rats. Cancer Res. 1979; 39: 1279–1286
   PubMed Web of Science ®Google Scholar
• DeSimone P. A., Yancey R. S., Coupal J. J., Butts J. D., Hoeschel J. D. Effect of a Forced Diuresis on the Distribution and Excretion (via Urine and Bile) of 195m Platinum When Given as 195m Platinum Cis-diamminedichloroplatinum(II). Cancer Treat. Rep. 1979; 63: 951–960
   PubMedGoogle Scholar
• Nagai N., Ogata H. The Renal Clearance of Unchanged Cisplatin During Furosemide and Mannitol Diuresis Is Dependent on Glomerular Filtration Rate in Rats. J. Pharm. Sci. 1996; 85: 720–724
   PubMedGoogle Scholar
• Fujimura A., Shiga T., Ohashi K., Ebihara A. Daily Variation in the Effects of Furosemide in Rats. Jpn. J. Pharmacol. 1992; 60: 323–326
   PubMedGoogle Scholar
• Boughattas A. N., Foutnier C., Hecquet B., Lemaigre G., Roulon A., Reinberg A., Mathé G., Leacute;vi F. Circadian Time Dependent Tissue Uptake of Cisplatin and Carboplatin Following Repeated Administration: Relationship with Drug Toxicities. Annual Review of Chronopharmacology, A. Reinberg, M. Smolensky, G. Labreque. Pergamon Press, OxfordUK 1990; 7: 231–234
   Google Scholar
• Touitou Y., Focan C. Rhythms in Tumor Markers. Biologic Rhythms in Clinical and Laboratory Medicine, Y. Touitou, E. Haus. Springer-Verlag, Berlin 1992; 648–657
   Google Scholar
• Mormont M. C., Lévi F. Circadian-System Alterations During Cancer Processes: A Review. Int. J. Cancer 1997; 70: 241–247
   PubMed Web of Science ®Google Scholar
• Mormont M. C., Waterhouse J., Bleuzen P., Giacchetti S., Jami A., Lellouch J., Misset J. L., Touitou Y., Leévi F. Marked 24-h Rest/Activity Rhythms Are Associated with Better Quality of Life, Better Response, and Longer Survival in Patients with Metastatic Colorectal Cancer and Good Performance Status. Clin. Cancer Res. 2000; 6: 3030–3045
   Google Scholar
• Sephton S. E., Sapolosky R. M., Kraemer H. C., Spiegel D. Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival. J. Natl. Cancer Inst. 2000; 92: 994–1000
   PubMed Web of Science ®Google Scholar
• Barret R., Blessing J., Webster K., Twiggs L. Circadian-Timed Combination Doxorubicin-Cisplatin Chemotherapy for Advanced Endometrial Carcinoma. Gynecol. Oncol. 1990; 36: 285–297
   Google Scholar
• Bruguerolle B., Lévi F., Arnaud C., Bouvenout G., Mechkouri M., Vannetzel J. M., Touitou Y. Alteration of Physiological Circadian Time Structure of Six Plasma Proteins in Patients with Advanced Cancer. Annual Review of Chronopharmacology, A. Reinberg, M. Smolensky, G. Labrecque. Pergamon Press, OxfordUK 1984; 3: 207–210
   Google Scholar